REPL Replimune Group Inc: Enterprise Value-to-Revenue Multiple

Public company logo of replimune.com (REPL)

Replimune Group, Inc. (REPL) develops unique oncolytic viruses that destroy tumors, transforming them into sources for their own vaccines. The enterprise value-to-revenue multiple visualizes the real price of the business excluding debt, where 0.00 shows the current value of this metric. The model is based on the RPx platform, which integrates medical centers through exclusive protocols. Replimune Group, Inc. (REPL) maintains its status as a promising innovator with high trust from the scientific community.

Company Value to Revenue: Replimune Group Inc (REPL) for 11/23/2025 - 11/20/2026

replimune.com - analytical breakdowns and key metrics (REPL)

- share price and consensus valuation forecast:
Initial company analysis:Replimune Group, Inc. REPL
Product sample of Replimune Group, Inc.

For Replimune Group, Inc., a developer of cancer immunotherapy, this indicator determines the market value of the business relative to its operating revenues. The metric excludes the impact of debt obligations, revealing the pure fundamental value of the assets. Analyzing the company's valuation based on revenue without accounting for debt allows for the elimination of financial noise. Sharp spikes in the trajectory signal overvaluation amid geopolitical risks that are hindering clinical trials. A stable trend confirms the resilience of the capitalization to external shocks.

Competitor analysis for Replimune Group, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP